Regeneron Pharmaceuticals recently received U.S. FDA approval and a positive opinion from the European Medicines Agency's ...
In a note to investors on Sunday, analysts at Leerink Partners called these findings “compelling,” adding that they indicate ...
The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ immunotherapy, Libtayo, as an add-on ...
In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...
In February, the biotech reported improvements in 10 of 11 children who received DB-OTO. The AAV gene therapy, which ...
Patients are asking to join clinical trials of antibody-based COVID-19 drugs after U.S. President Donald Trump was treated last week with an experimental therapy from Regeneron Pharmaceuticals Inc , ...
Regeneron's Libtayo gains FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, enhancing ...
New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell ...
FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, ...
Regeneron’s monoclonal antibody trevogrumab, with or without the anti-activin A antibody garetosmab, appears to preserve lean ...
A 3-year-old girl who underwent a breakthrough gene therapy treatment to treat profound hearing loss can hear on her own, two ...
Regeneron Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster cancer drug Libtayo for certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback